Lutetium Lu 177 Lilotomab-satetraxetan

**Semantic type:** Pharmacologic Substance

**Definition:** A radioconjugate consisting of lilotomab, a murine immunoglobulin G1 (IgG1) antibody directed against the CD37 antigen, conjugated via the chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (p-SCN-Bn-DOTA) with potential antineoplastic activities. Upon administration of lutetium Lu 177 lilotomab-satetraxetan, the lilotomab moiety binds to CD37 expressed on certain tumor cells. Upon binding, lutetium Lu 177 lilotomab-satetraxetan delivers a cytotoxic dose of beta radiation to CD37-expressing cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell lymphomas.

**Synonyms:** - 177Lu Lilotomab Satetraxetan - 177Lu-Lilotomab-satetraxetan - Betalutin - LUTETIUM (LU177) LILOTOMAB SATETRAXETAN - Lutetium Lu-177 Lilotomab Satetraxetan - Lutetium Lu-177 Lilotomab-satetraxetan